Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 29, 2007

Asuragen Accesses Xenomic’s NPM1 Technology for Diagnostic Development

  • Xenomics granted Asuragen coexclusive, worldwide rights to incorporate NPM1 technology into Asuragen's molecular diagnostic products. Under the terms of this agreement, Asuragen will have the right to develop, manufacture, and market products for the diagnosis, stratification, and monitoring of patients with acute myeloid leukemia (AML).

    A recent discovery, for which Xenomics holds exclusive rights, showed that many AML patients have mutations in the nucleophosmin (NPM1) gene, a favorable marker for clinical outcome. It is hoped that the results of such a test will help physicians select patients with a good prognosis of benefiting from intensive chemotherapy.

    The NPM1 mutation may also be used to monitor AML patients for residual disease during chemotherapy.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »